Daily Cardiology

Long-term event-free and overall survival with Dapagliflozin in HFrEF patients

15 Jan 2022

Contributed by Lukas

Impact of Dapagliflozin on the survival of HFrEF patients

Milrinone compared with Dobutamine in cardiogenic shock: DOREMI trial

15 Jan 2022

Contributed by Lukas

Milrinone vs. Dobutamine: DOREMI trial

Dapagliflozin in non-DM Patients with HF and Reduced EF

15 Jan 2022

Contributed by Lukas

The findings of DAPA-HF trial in non-diabetics

Benefits of Targeting for a

15 Jan 2022

Contributed by Lukas

The findings of TST study

Electrical versus pharmacological cardioversion for acute AF in emergency settings

15 Jan 2022

Contributed by Lukas

The findings of RAFF2 trial

Daily Cardiology Journal Club: First Session – How to setup an effective Journal Club?

15 Jan 2022

Contributed by Lukas

Monthly Case-Based Clinical Problem Solving

Dapagliflozin in concurrent Atrial Fibrillation and T2DM

15 Jan 2022

Contributed by Lukas

Insights from DECLARE-TIMI 58 Trial

Daily Cardiology Journal Club: First Session – How to setup an effective Journal Club?

15 Jan 2022

Contributed by Lukas

Monthly Case-Based Clinical Problem Solving

Daily Cardiology Journal Club: 3rd Session – EMPEROR-REDUCED Trial

15 Jan 2022

Contributed by Lukas

Monthly Case-Based Clinical Problem Solving

Predicting the Risk of Post-stroke Atrial Cardiopathy

15 Jan 2022

Contributed by Lukas

An interim analysis from ACARDIA trial

Intensive LDL lowering beyond current recommendations for MACE prevention

15 Jan 2022

Contributed by Lukas

A meta-analysis of RCTs

Daily Cardiology Journal Club: 4th Session – EAST-AFNET4 Trial

15 Jan 2022

Contributed by Lukas

Monthly Case-Based Clinical Problem Solving

OACs vs. antiplatelet or placebo for stroke prevention in patients with HF and sinus rhythm

15 Jan 2022

Contributed by Lukas

A meta-analysis of RCTs

Association of Anticoagulation Therapy with the Risk of Fracture in AF Patients

15 Jan 2022

Contributed by Lukas

The findings of a recent study

Intensive Blood Pressure lowering and the Concerns about Falling

15 Jan 2022

Contributed by Lukas

The findings of SPRINT trial

Daily Cardiology Journal Club: Second Session – ISCHEMIA Trial

15 Jan 2022

Contributed by Lukas

Monthly Case-Based Clinical Problem Solving

Complete vs. Culprit-only Revascularization in Patients with STEMI and Multi-Vessel Coronary Disease

15 Jan 2022

Contributed by Lukas

A meta-analysis of RCTs

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in T2DM

15 Jan 2022

Contributed by Lukas

The renal and cardiovascular protective effects of SGLT2 inhibitors

Timing of Staged Non-Culprit Artery PCI in STEMI

15 Jan 2022

Contributed by Lukas

The findings of COMPLETE Trial about PCI timing

Inclisiran for patients with ASCVD and elevated LDL

15 Jan 2022

Contributed by Lukas

The findings of ORION-10 trial in ASCVD patients

The Efficacy and Safety of Low-Dose Colchicine after MI

15 Jan 2022

Contributed by Lukas

The findings of COLCOT trial about colchicine post-MI

Optimal Medical Therapy vs. Revascularization in Chronic Coronary Syndrome

15 Jan 2022

Contributed by Lukas

The findings of ISCHEMIA trial

Antithrombotic treatment after CABG

15 Jan 2022

Contributed by Lukas

A recent meta-analysis on post-CABG Antithrombotic therapy

Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis

15 Jan 2022

Contributed by Lukas

The findings of RECOVERY trial

AF after Non-Cardiac Surgery Increases the Risk of Stroke

15 Jan 2022

Contributed by Lukas

A meta-analysis of post-operative AF studies

Triglyceride Lowering and Cardiovascular Risk Reduction

15 Jan 2022

Contributed by Lukas

A Systematic Review and Meta-Analysis of RCTs on TG lowering drugs

Inclisiran in Heterozygous Familial Hypercholesterolemia (HeFH) and Elevated LDL

15 Jan 2022

Contributed by Lukas

The findings of ORION-9 trial about Inclisiran in HeFH

Rivaroxaban vs. Vit K Antagonist in Antiphospholipid Syndrome

15 Jan 2022

Contributed by Lukas

Rivaroxaban versus warfarin in APS

Ticagrelor with or without Aspirin in High-Risk patients after PCI

15 Jan 2022

Contributed by Lukas

The findings of TWILIGHT Trial

Lisinopril vs Carvedilol for Trastuzumab Cardiotoxicity in Breast Cancer

15 Jan 2022

Contributed by Lukas

Preventing the cardiotoxicity of Trastuzumab

Acute vs Subacute Coronary Angiography in NSTEMI

15 Jan 2022

Contributed by Lukas

The findings of NONSTEMI Trial

Peri-operative beta-blockers in non-cardiac surgery

15 Jan 2022

Contributed by Lukas

The findings of Cochrane database systematic review

Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy

15 Jan 2022

Contributed by Lukas

The findings of STICH trial

OAC Monotherapy in Patients with Stable CAD and Non-valvular AF

15 Jan 2022

Contributed by Lukas

OACs in Stable CAD and AF

Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI

15 Jan 2022

Contributed by Lukas

P2Y12 loading dose timing in PCI

Pantoprazole in Patients Receiving Rivaroxaban and/or Aspirin

15 Jan 2022

Contributed by Lukas

The findings of COMPASS trial

Risk of Mortality Following Catheter Ablation of AF

15 Jan 2022

Contributed by Lukas

Mortality risk after AF ablation

Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease

15 Jan 2022

Contributed by Lukas

The findings of EXCEL Trial

Restarting Antiplatelet After ICH Cuts Recurrence Risk in Half

15 Jan 2022

Contributed by Lukas

The findings of REASTART Trial

Bedtime hypertension treatment improves cardiovascular risk reduction

15 Jan 2022

Contributed by Lukas

The findings of Hygia Chronotherapy Trial

Ezetimibe for the prevention of heart disease and death

15 Jan 2022

Contributed by Lukas

The role of Ezetimibe in reducing CVD adverse outcomes

Anticoagulation in HF and sinus rhythm

15 Jan 2022

Contributed by Lukas

OACs in HF and sinus rhythm

TAVR vs SAVR: insights from ACC.19

15 Jan 2022

Contributed by Lukas

The findings of PARTNER 3 and EVOLUT trials

Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or TIA

15 Jan 2022

Contributed by Lukas

DAPT after ischemic stroke or TIA

Antithrombotic Therapy after ACS or PCI in AF

15 Jan 2022

Contributed by Lukas

The findings of AUGUSTUS Trial

Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis

15 Jan 2022

Contributed by Lukas

Stenting vs endarterectomy in symptomatic carotid stenosis

Canagliflozin and Renal Outcomes in T2Dm and Nephropathy

15 Jan 2022

Contributed by Lukas

The findings of CREDENCE Trial

Hypertension and Hyperlipidemia Academy: 4th session

14 Jan 2022

Contributed by Lukas

H&H Academy session 4

Ticagrelor Hub: when to use and which dose?

14 Jan 2022

Contributed by Lukas

The dosage and indications of Ticagrelor

Management of dyslipidemia in diabetic patients

14 Jan 2022

Contributed by Lukas

DLP and T2DM: approach and management

Umbrella Heart and Stroke: session 1, detecting & managing patients with PFO

14 Jan 2022

Contributed by Lukas

Umbrella H&S: session1, PFO

Primary prevention in dyslipidemia as the only cardiovascular risk factor

14 Jan 2022

Contributed by Lukas

Dyslipidemia in primary prevention of low-risk patients

Late-breaking Science in Cardiovascular disease prevention

14 Jan 2022

Contributed by Lukas

ESC 2021 cardiovascular prevention guideline lectures and discussion

DiaBeat: The Beating Heart of Diabetes (8th session)

14 Jan 2022

Contributed by Lukas

8th Diabetes Masterclass for Cardiologists

Cardiometabolic Grand Round (5)

14 Jan 2022

Contributed by Lukas

The 5th session of Cardiometabolic grand round

An introduction to a new series; HeartCast

14 Jan 2022

Contributed by Lukas

HeartCast introduction

The clinical landscape for Diabetes and Cardiovascular disease

14 Jan 2022

Contributed by Lukas

T2DM and cardiovascular diseases: The clinical landscape

Hypertension and Hyperlipidemia Academy 5, a hybrid event

14 Jan 2022

Contributed by Lukas

5th session of H&H Academy, online and onsite

DiaBeat: The Beating Heart of Diabetes (6th session)

14 Jan 2022

Contributed by Lukas

6th Diabetes Masterclass for Cardiologists

Symptom matters: angina control in coronary artery disease

14 Jan 2022

Contributed by Lukas

From surrogates to symptom control in CAD

Marking the antiplatelet therapy maze in ACS

14 Jan 2022

Contributed by Lukas

How to prevent atherosclerotic cardiovascular events

DiaBeat: The Beating Heart of Diabetes (7th session), a scientific debate

14 Jan 2022

Contributed by Lukas

7th Diabetes Masterclass for Cardiologists

Antithrombotic lighthouse, Cases and Faces: antithrombotic therapy in CAD

14 Jan 2022

Contributed by Lukas

Antithrombotic regimens in CAD

From optimal medical therapy to revascularization in CCS

14 Jan 2022

Contributed by Lukas

Choosing the best therapeutic strategy in CCS

Cardiovascular complications of T2DM: the preventive role of SGLT2Is

14 Jan 2022

Contributed by Lukas

SGLT2Is and the prevention of cardiovascular complications in T2DM

Cardiometabolic Grand Round (4)

14 Jan 2022

Contributed by Lukas

Guideline-directed cardiovascular evaluations before surgery

Tailored Antithrombotic therapy for CCS patients

14 Jan 2022

Contributed by Lukas

Best individual antithrombotic strategy in CCS

DCS 1400: session 8, Valvular Heart disease

14 Jan 2022

Contributed by Lukas

The eighth panel of DCS 1400: Valvular Heart disease

The evolution of antiplatelet therapy in CAD: a 45 year journey

14 Jan 2022

Contributed by Lukas

A brief history of anti-platelet therapy in CAD

Dual antiplatelet therapy in2021: Current recommendations

14 Jan 2022

Contributed by Lukas

The latest updates on DAPT

How to reduce the atherosclerotic cardiovascular risk

14 Jan 2022

Contributed by Lukas

A case-based Review on HTN and DLP management

DiaBeat: The Beating Heart of Diabetes (1st session)

14 Jan 2022

Contributed by Lukas

1st Diabetes Masterclass for Cardiologists

PCSK9 inhibitors place in patients with cardiometabolic diseases

14 Jan 2022

Contributed by Lukas

PCSK9 inhibitors from two perspectives of Endocrinologist & Cardiologist

Residents’ Island: Abidi CVD Prevention Academy

14 Jan 2022

Contributed by Lukas

Multidisciplinary approach to CVD Prevention

Cardiometabolic Grand Round (3)

13 Jan 2022

Contributed by Lukas

A brief talk on DM medication challenges in patients with CVD

7th Case: Thrombocytopenia

13 Jan 2022

Contributed by Lukas

Any Concerns for OACs Use in Patients with Thrombocytopenia

5th Case: Stable ASCVD

13 Jan 2022

Contributed by Lukas

Low dose Rivaroxaban in SIHD, COMPASS trial

6th Case: Hepatic Impairment

13 Jan 2022

Contributed by Lukas

OAC of choice in patients with hepatic impairment, any difference between DOACs?

8th Case: Intracranial Bleed

13 Jan 2022

Contributed by Lukas

OAC Choice in High Thrombotic Risk Patients after ICH

10th Case: Drug Drug Interactions

13 Jan 2022

Contributed by Lukas

DOACs important interactions in clinical practice

9th Case: Renal Insufficiency

13 Jan 2022

Contributed by Lukas

OAC Management in Patients with CKD

4th Case: Extreme Body Weights

13 Jan 2022

Contributed by Lukas

OAC choice in patients with obesity or low body weights, any role for DOACs?

3rd Case: AF & Artificial Heart Valves

13 Jan 2022

Contributed by Lukas

OAC of choice in patients with artificial heart valves

2nd Case: Cancer associated VTE

13 Jan 2022

Contributed by Lukas

Anticoagulation of choice in patients with cancer, the importance of DDI

1st Case: Elective PCI and AF

13 Jan 2022

Contributed by Lukas

Antithrombotic regimen of choice in patients with AF undergoing elective PCI

SGLT2 inhibition: A snapshot into their evolution

13 Jan 2022

Contributed by Lukas

Endocrinologist Perspective on SGLT2 inhibitors

SGLT2 inhibition: Making waves in the heart failure landscape

12 Jan 2022

Contributed by Lukas

Role of SGLT2 inhibitors in HF patients from two perspectives: Endocrinology & Cardiology

Cardiometabolic Grand Round (2)

12 Jan 2022

Contributed by Lukas

A brief talk on DM medication challenges in patients with CVD

Paradigm Shift in Treating Intermediate Risk Pulmonary Embolism

11 Jan 2022

Contributed by Lukas

Concise Talk on Intermediate Risk Pulmonary Embolism, update by an expert in the field

How to Implement the Newest Diabetes Therapies in HF Treatment

11 Jan 2022

Contributed by Lukas

New insight from EMPEROR Reduced Trial

What we learned from ESC Congress about HTN Management

11 Jan 2022

Contributed by Lukas

A Brief Discussion on HTN Management Pearls of ESC 2020

VTE Prophylaxis in Patients with COVID-19

11 Jan 2022

Contributed by Lukas

Challenges on VTE Prophylaxis in different settings (inpatient, outpatient, upon discharge)

ESC 2020 Congress Coverage What is new on NSTE-ACS Guideline: a panel discussion

11 Jan 2022

Contributed by Lukas

Brief Discussion on the New ESC Guideline on NSTE-ACS

Diabetes and Cardiovascular Diseases

11 Jan 2022

Contributed by Lukas

On the occasion of World Heart Day 2020 for the management of Cardiovascular risk factors

Smoking and the Heart the Struggle Continues

11 Jan 2022

Contributed by Lukas

On the occasion of World Heart Day 2020 for the management of Cardiovascular risk factors

Ground-breaking research from ESC Congress 2020 (23)

11 Jan 2022

Contributed by Lukas

Part Twenty-three: Trial Review, ELDERCARE-AF

Ground-breaking research from ESC Congress 2020 (21)

11 Jan 2022

Contributed by Lukas

Part Twenty-One: Trial Review, BPLTTC (CANCER)

Ground-breaking research from ESC Congress 2020 (22)

11 Jan 2022

Contributed by Lukas

Part Twenty-Two: Trial Review, ATPCI

Ground-breaking research from ESC Congress 2020 (17)

10 Jan 2022

Contributed by Lukas

Part Seventeen: Trial Review, REALITY

Ground-breaking research from ESC Congress 2020 (15)

10 Jan 2022

Contributed by Lukas

Part Fifteen: Trial Review, PARALLAX